St. Vincent Hospital
United States
Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium
The Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium is a collaboration among three major cancer care systems in Wisconsin: St. Vincent Hospital Cancer Centers (SVHCC), Wheaton Franciscan Healthcare - Southeast Wisconsin, Inc., Ministry Healthcare, Inc., and Columbia St. Mary’s, Inc. (collectively, Ascension Wisconsin), and Aspirus, Inc. SVHCC serves as the primary performance site. Together, these institutions and their affiliates provide access to National Cancer Institute (NCI)-sponsored clinical trials across a wide geographic region that includes both urban and rural areas in Wisconsin and northern Michigan. The CROWN Consortium aims to broaden participation in clinical trials through expanded recruitment infrastructure, shared operational resources, and regular coordination via established consortium committees. The consortium supports implementation of Cancer Care Delivery Research (CCDR) across multiple sites and actively contributes to NCORP Research Base activities, including committee service, protocol input, and mentoring of early-career investigators. The CROWN Consortium brings a robust research infrastructure and multidisciplinary expertise across medical and radiation oncology, pediatric oncology, and palliative care. It offers a comprehensive portfolio of clinical trials to the community setting, including studies in cancer prevention, control, care delivery, imaging, treatment, and biospecimen collection. These efforts serve to increase trial access and generate broadly applicable research findings from a range of practice settings. The specific aims of the CROWN Consortium include 1) broadening consortium participation in NCI-sponsored clinical trials by expanding recruitment, clinical capabilities, and resource sharing; 2) execution of high-quality Cancer Care Delivery Research (CCDR) across the consortium; and 3) increasing investigator engagement in NCORP initiatives by contributing to best practices and research findings. The CROWN Consortium strengthens the NCORP network by expanding access to clinical trials through the implementation and evaluation of trials across the community oncology landscape.
Publications
- Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848
- Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
- Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2):186-197. Epub 2022 Sep 27. PMID: 36166727
- Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. PMID: 38236702